A placebo-controlled, randomized, rising multiple dose study of ADV-1002401 to evaluate safety, tolerability, pharmacokinetics and pharmacodynamics in adult male Type-II diabetic subjects - NIL

开始日期2011-04-04

申办/合作机构-

CTRI/2010/091/000275 / Completed临床1期

A First in Human, Placebo-Controlled, Randomized, Double-Blind, Rising Single Dose Study of ADV-1002401 to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Healthy, Adult Volunteers and Adult Type-II Diabetic Volunteers - Phase 01 Study

开始日期2010-03-20

申办/合作机构-

100 项与 GKM-001 相关的临床结果

登录后查看更多信息

100 项与 GKM-001 相关的转化医学

登录后查看更多信息

100 项与 GKM-001 相关的专利（医药）

登录后查看更多信息

项与 GKM-001 相关的文献（医药）

2018-04-01·Science of The Total Environment2区 · 环境科学与生态学

Real world CO2 and NOx emissions from 149 Euro 5 and 6 diesel, gasoline and hybrid passenger cars

2区 · 环境科学与生态学

Article

作者: Stettler, Marc E J ; Oxley, Tim ; O'Driscoll, Rosalind ; ApSimon, Helen M ; Molden, Nick

In this study CO₂ and NO_x emissions from 149 Euro 5 and 6 diesel, gasoline and hybrid passenger cars were compared using a Portable Emissions Measurement System (PEMS). The models sampled accounted for 56% of all passenger cars sold in Europe in 2016. We found gasoline vehicles had CO₂ emissions 13-66% higher than diesel. During urban driving, the average CO₂ emission factor was 210.5 (sd. 47) gkm^-1 for gasoline and 170.2 (sd. 34) gkm^-1 for diesel. Half the gasoline vehicles tested were Gasoline Direct Injection (GDI). Euro 6 GDI engines <1.4ℓ delivered ~17% CO₂ reduction compared to Port Fuel Injection (PFI). Gasoline vehicles delivered an 86-96% reduction in NO_x emissions compared to diesel cars. The average urban NO_x emission from Euro 6 diesel vehicles 0.44 (sd. 0.44) gkm^-1 was 11 times higher than for gasoline 0.04 (sd. 0.04) gkm^-1. We also analysed two gasoline-electric hybrids which out-performed both gasoline and diesel for NO_x and CO₂. We conclude action is required to mitigate the public health risk created by excessive NO_x emissions from modern diesel vehicles. Replacing diesel with gasoline would incur a substantial CO₂ penalty, however greater uptake of hybrid vehicles would likely reduce both CO₂ and NO_x emissions. Discrimination of vehicles on the basis of Euro standard is arbitrary and incentives should promote vehicles with the lowest real-world emissions of both NO_x and CO₂.

Pharmaceuticals

Managing Post-Transplant Diabetes Mellitus after Kidney Transplantation: Challenges and Advances in Treatment

Review

作者: Piasecka, Zuzanna ; Rudzki, Grzegorz ; Woźniak, Magdalena ; Głaz, Aneta ; Kochanowska-Mazurek, Anna ; Wesołek-Bielaska, Ewelina ; Knop-Chodyła, Kinga

Kidney transplantation is the most effective treatment for end-stage renal failure but is associated with complications, including post-transplant diabetes mellitus (PTDM). It affects the quality of life and survival of patients and the transplanted organ. It can cause complications, including infections and episodes of acute rejection, further threatening graft survival. The prevalence of PTDM, depending on the source, can range from 4 to 30% in transplant patients. This article aims to discuss issues related to diabetes in kidney transplant patients and the latest treatments. Knowledge of the mechanisms of action of immunosuppressive drugs used after transplantation and their effect on carbohydrate metabolism is key to the rapid and effective detection of PTDM. Patient therapy should not only include standard management such as lifestyle modification, insulin therapy or pharmacotherapy based on well-known oral and injection drugs. New opportunities are offered by hypoglycemic drugs still in clinical trials, including glucokinase activators, such as dorzagliatin, ADV-1002401, LY2608204, TMG-123, imeglimine, amycretin and pramlintide. Although many therapeutic options are currently available, PTDM often creates uncertainty about the most appropriate treatment strategy. Therefore, more research is needed to individualize therapeutic plans and monitor these patients.

100 项与 GKM-001 相关的药物交易

登录后查看更多信息